Consequently, pan-BET inhibitors (BETi) show promising anti-tumour activity in diverse pre-clinical models albeit with some limitations (Zuber et al, 2011; Shu et al, 2016; Cheng et al, 2013). This evidence concerns the gene DNER and neoplasm.